The WHI study changed everything — and most of it was wrong

If one piece of medical history explains why menopause care is where it is today, it’s the Women’s Health Initiative trial — the WHI — whose results were announced in July 2002. The press conference moved markets. By the end of that year, prescriptions for hormone therapy had fallen off a cliff, and a generation of doctors quietly stopped offering it.

The headline: women on HRT had higher rates of breast cancer, heart attacks, and strokes. The implication the public took home: HRT is dangerous.

Here’s what the headline left out.

The trial didn’t study the women who would take HRT today

The average participant in the WHI was 63 years old — more than a decade past her last period, and well past the age most women today would even consider starting hormone therapy. For many of those women, starting estrogen that late does carry different risks than starting it during perimenopause or in the early postmenopausal years.

This is the “timing hypothesis,” and subsequent re-analyses of the WHI data — done by the WHI investigators themselves — have confirmed it: in women under 60 or within 10 years of menopause, the risk picture flips. Cardiovascular mortality goes down. The absolute risk of breast cancer remains extremely small, and disappears entirely with certain combinations.

The drug wasn’t what we’d prescribe now

The estrogen used in the WHI was conjugated equine estrogens — Premarin, extracted from pregnant mare urine. The progestin was medroxyprogesterone acetate — a synthetic that we now know is associated with a meaningfully different risk profile than micronized (bioidentical) progesterone.

Modern perimenopause care uses bioidentical transdermal estradiol plus micronized progesterone. That is not the same drug combination that scared your mother’s doctor in 2002.

Why the correction took twenty years to reach clinics

Medicine is slow. The same doctors who’d been traumatized by 2002 didn’t spend the next decade re-reading the updated analyses. Residency curricula didn’t update. Patients kept getting the old answer. And a whole generation of women in their forties and fifties were, quietly, systematically under-treated.

The data has moved. The conversation, finally, is catching up.